Meghan Rego received her PhD from the University of Rhode Island studying the molecular etiology of the cancer susceptibility syndrome, Fanconi Anemia. Before joining Addgene to help launch their viral vector service in 2016, Meghan worked at a variety of biotechnology and pharmaceutical companies focused on therapeutic biologics. In her current role as Director of Antibodies, Meghan is focused on building Addgene's recombinant antibody production and quality control platform. She is excited to bring high quality, open-access antibodies to scientists.